Aspire Biopharma Files Patent for Fast-Acting Sublingual Meclizine Formulation
Aspire Biopharma filed a provisional patent application for a sublingual powder formulation of meclizine on February 17, 2026, designed to reduce onset time from 60 minutes to minutes. The company plans a 505(b)(2) regulatory pathway for the antiemetic targeting a $450 million global market.
Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its proprietary sublingual powder formulation of meclizine on February 17, 2026. The application, titled "A Sublingual Powder Formulation of Meclizine and Methods of Use Thereof," represents the first-ever sublingual powder delivery system for meclizine, aiming to eliminate the traditional "waiting period" associated with oral tablets and provide near-instant relief for nausea, vomiting, and vertigo.
Meclizine was the top-prescribed antiemetic/antivertigo agent in 2023, with approximately 4.09 million prescriptions in the United States. The global meclizine market is valued at $450 million and is projected to grow to $650 million by 2032.
Standard oral administration of meclizine typically requires one hour to begin working and up to three hours to reach peak plasma levels. Aspire's sublingual platform is engineered to redefine this standard through rapid systemic entry by bypassing the gastrointestinal tract and first-pass metabolism. The formulation targets rapid-onset relief, aiming to cut typical oral onset from about 60 minutes to minutes.
The company plans to pursue a 505(b)(2) regulatory pathway to potentially accelerate clinical development. However, the provisional filing does not guarantee patent grant or enforceable rights, and no clinical efficacy data has been published yet to confirm faster onset or safety.
Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. The delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning small molecule therapeutics, nutraceuticals and supplements.